Bexarotene – an alternative therapy for progressive cutaneous T‐cell lymphoma? First experiences

Background: A standard therapy for advanced cutaneous T‐cell lymphomas has not yet been defined. Bexarotene is a new retinoid x receptor‐specific retinoid that has been approved for systemic second‐line therapy for cutaneous T‐cell lymphomas in the USA and Europe. In order to evaluate the efficacy of bexarotene in cutaneous T‐cell lymphomas, a pilot trial was initiated.

[1]  R. Stadler.  Treatment of Cutaneous T Cell Lymphoma , 2002, Skin Pharmacology and Physiology.

[2]  H. Prince,et al.  RESEARCH REPORT Bexarotene capsules and gel for previously treated patients with cutaneous T‐cell lymphoma: Results of the Australian patients treated on phase II trials , 2001 .

[3]  G. Wood,et al.  Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.

[4]  M. Duvic,et al.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Kaatz,et al.  Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. , 2000, Oncology reports.

[6]  R. Heyman,et al.  Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. , 1999, Journal of the National Cancer Institute.

[7]  M. Kashani-Sabet,et al.  Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. , 1999, Journal of the American Academy of Dermatology.

[8]  W. Sterry,et al.  Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. , 1998, Blood.

[9]  S. Whittaker,et al.  Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. , 1998, Archives of dermatology.

[10]  N. Noy,et al.  Heterodimer formation by retinoid X receptor: regulation by ligands and by the receptor's self-association properties. , 1998, Biochemistry.

[11]  M. Ratain,et al.  Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. , 1998, Blood.

[12]  H. Kerl,et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.

[13]  M. Kris,et al.  Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Varghese,et al.  Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. , 1995, Archives of dermatology.

[15]  L. Golitz,et al.  Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome) , 1994, Annals of Internal Medicine.

[16]  F. Gasparro,et al.  Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. , 1992, Journal of the American Academy of Dermatology.

[17]  James T. Elder,et al.  Retinoic acid receptor gene expression in human skin. , 1991, Journal of Investigative Dermatology.

[18]  E. Bisaccia,et al.  Photopheresis for the treatment of cutaneous T cell lymphoma. , 1990, Journal of the American Academy of Dermatology.

[19]  A. Markoe,et al.  The radiation therapy of early stage cutaneous T-cell lymphoma. , 1990, International journal of radiation oncology, biology, physics.

[20]  M. Weinstock,et al.  Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. , 1988, JAMA.

[21]  L. Brady,et al.  Combined moderate dose electron beam radiotherapy and topical chemotherapy for cutaneous T-Cell lymphoma. , 1983, International journal of radiation oncology, biology, physics.

[22]  S. E. Whitmore.  Optimizing bexarotene therapy for cutaneous T-cell lymphoma. , 2004, Journal of the American Academy of Dermatology.

[23]  U. Wollina,et al.  Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. , 2000, Journal of the American Academy of Dermatology.

[24]  Bexarotene (Targretin) for cutaneous T-cell lymphoma. , 2000, The Medical letter on drugs and therapeutics.

[25]  R. Stadler,et al.  Therapie des SézarySyndroms durch extrakorporale Photochemotherapie , 1996, Der Hautarzt.